Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
100 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Myasthenia Gravis - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Myasthenia Gravis - Pipeline Review, H1 2015', provides an overview of the Myasthenia Gravis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Myasthenia Gravis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myasthenia Gravis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Myasthenia Gravis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Myasthenia Gravis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Myasthenia Gravis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Myasthenia Gravis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myasthenia Gravis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myasthenia Gravis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Myasthenia Gravis Overview 8 Therapeutics Development 9 Pipeline Products for Myasthenia Gravis - Overview 9 Pipeline Products for Myasthenia Gravis - Comparative Analysis 10 Myasthenia Gravis - Therapeutics under Development by Companies 11 Myasthenia Gravis - Therapeutics under Investigation by Universities/Institutes 13 Myasthenia Gravis - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Myasthenia Gravis - Products under Development by Companies 17 Myasthenia Gravis - Products under Investigation by Universities/Institutes 18 Myasthenia Gravis - Companies Involved in Therapeutics Development 19 Alexion Pharmaceuticals, Inc. 19 Alnylam Pharmaceuticals, Inc. 20 Astellas Pharma Inc. 21 Biokine Therapeutics Ltd. 22 CuraVac, Inc. 23 Cytokinetics, Inc. 24 GlaxoSmithKline plc 25 Grifols, S.A. 26 HanAll Biopharma Co., Ltd. 27 Neurotune AG 28 Pfizer Inc. 29 Regenesance BV 30 Toleranzia AB 31 Myasthenia Gravis - Therapeutics Assessment 32 Assessment by Monotherapy Products 32 Assessment by Target 33 Assessment by Mechanism of Action 35 Assessment by Route of Administration 37 Assessment by Molecule Type 39 Drug Profiles 41 ALN-CC5 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 belimumab - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 BKT-130 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 CK-2066260 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 eculizumab - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 GL-2045 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 HL-161 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 immune globulin (human) - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 NT-1654 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Recombinant Protein for Myasthenia Gravis - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Recombinant Protein to Antagonize LTB4 and C5 for Respiratory, Immunological, CNS and Hematological Disorders - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Regenemab - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 tacrolimus - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 tirasemtiv - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Vaccine for Myasthenia Gravis - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Vaccine for Myasthenia Gravis - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Myasthenia Gravis - Recent Pipeline Updates 69 Myasthenia Gravis - Dormant Projects 85 Myasthenia Gravis - Discontinued Products 86 Myasthenia Gravis - Product Development Milestones 87 Featured News & Press Releases 87 Dec 10, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Myasthenia Gravis 87 Sep 16, 2014: Alnylam Presents New Pre-Clinical Data with ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 in Development for the Treatment of Complement-Mediated Diseases 88 Aug 01, 2014: European Commission Grants Orphan Drug Designation to Soliris (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG) 89 Jun 17, 2014: FDA Grants Orphan Drug Designation to Soliris (eculizumab) for the Treatment of Patients with Myasthenia Gravis 90 Jun 09, 2014: Alnylam Presents New Pre-Clinical Data with Development Candidate for ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 in Development for the Treatment of Complement-Mediated Diseases 90 Apr 24, 2014: Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica and Refractory Generalized Myasthenia Gravis 92 Apr 24, 2014: Toleranzia supported by VINNOVA 93 Dec 08, 2013: New Alnylam Pre-clinical Results on ALN-CC5, an RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases, Demonstrate up to 98% Serum C5 Knockdown and up to 94% Inhibition of Hemolytic Activity in Non-Human Primates 93 Jun 20, 2013: Alnylam Scientists Present Preclinical Data With ALN-CC5 For Treatment Of Complement-mediated Diseases 96 Mar 21, 2013: Cytokinetics Announces Presentation Of Phase IIA Clinical Trial Data Of Tirasemtiv In Patients With Myasthenia Gravis 97 Appendix 99 Methodology 99 Coverage 99 Secondary Research 99 Primary Research 99 Expert Panel Validation 99 Contact Us 100 Disclaimer 100
List of Tables Number of Products under Development for Myasthenia Gravis, H1 2015 9 Number of Products under Development for Myasthenia Gravis - Comparative Analysis, H1 2015 10 Number of Products under Development by Companies, H1 2015 12 Number of Products under Investigation by Universities/Institutes, H1 2015 13 Comparative Analysis by Late Stage Development, H1 2015 14 Comparative Analysis by Clinical Stage Development, H1 2015 15 Comparative Analysis by Early Stage Development, H1 2015 16 Products under Development by Companies, H1 2015 17 Products under Investigation by Universities/Institutes, H1 2015 18 Myasthenia Gravis - Pipeline by Alexion Pharmaceuticals, Inc., H1 2015 19 Myasthenia Gravis - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015 20 Myasthenia Gravis - Pipeline by Astellas Pharma Inc., H1 2015 21 Myasthenia Gravis - Pipeline by Biokine Therapeutics Ltd., H1 2015 22 Myasthenia Gravis - Pipeline by CuraVac, Inc., H1 2015 23 Myasthenia Gravis - Pipeline by Cytokinetics, Inc., H1 2015 24 Myasthenia Gravis - Pipeline by GlaxoSmithKline plc, H1 2015 25 Myasthenia Gravis - Pipeline by Grifols, S.A., H1 2015 26 Myasthenia Gravis - Pipeline by HanAll Biopharma Co., Ltd., H1 2015 27 Myasthenia Gravis - Pipeline by Neurotune AG, H1 2015 28 Myasthenia Gravis - Pipeline by Pfizer Inc., H1 2015 29 Myasthenia Gravis - Pipeline by Regenesance BV, H1 2015 30 Myasthenia Gravis - Pipeline by Toleranzia AB, H1 2015 31 Assessment by Monotherapy Products, H1 2015 32 Number of Products by Stage and Target, H1 2015 34 Number of Products by Stage and Mechanism of Action, H1 2015 36 Number of Products by Stage and Route of Administration, H1 2015 38 Number of Products by Stage and Molecule Type, H1 2015 40 Myasthenia Gravis Therapeutics - Recent Pipeline Updates, H1 2015 69 Myasthenia Gravis - Dormant Projects, H1 2015 85 Myasthenia Gravis - Discontinued Products, H1 2015 86
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
